Bloodwork on a GLP-1
Most people on these drugs are monitored on a bathroom scale and nothing else. A short, cheap panel twice a year would catch nearly everything that quietly goes wrong.
Independent GLP-1 journalism
Your Body
Nausea, reflux, gallbladder, pancreatitis — risk in proportion.
59 pieces
Most people on these drugs are monitored on a bathroom scale and nothing else. A short, cheap panel twice a year would catch nearly everything that quietly goes wrong.
Nobody is going to tell you to give up coffee, and nobody should. But it interacts with three things this drug class has already made more fragile, and the interactions are all avoidable.
Nausea gets the attention because it arrives first and loudly. Constipation arrives in week three, never fully resolves for some people, and is the thing they eventually stop over.
Acute kidney injury on this drug class is almost never a direct drug effect. It is three days of vomiting in someone who did not think to replace the fluid, and it is entirely avoidable.
Repeated vomiting erodes enamel permanently, reflux does it more quietly, and any dental procedure involving sedation now needs the same conversation as surgery. None of this is on the leaflet.
A drug famous for slowing the gut down produces loose stools in a substantial minority, which sounds contradictory until you know what else is usually in the picture.
No blood service in the United States defers you for taking one of these. What will defer you is the iron, the weight and the hydration — three things this drug class makes considerably more likely.
The advice to exercise while losing weight is correct and almost always delivered by someone who has not tried doing it on nine hundred calories and a stomach that empties at half speed.
Rapid weight loss has caused gallstones for as long as people have lost weight rapidly. What these drugs added was the speed, the scale, and a great many people discovering it at once.
Periods returning, periods changing character, periods arriving on a schedule for the first time in years. It is one of the most commonly reported effects in this drug class and one of the least documented.
In 2023 the advice was to hold your weekly injection for a week. In 2024 a multi-society panel replaced that with something considerably more nuanced. Plenty of pre-op letters have not caught up.
The thyroid warning, the pancreatic scare and the colorectal signal are three different arguments with three different evidence bases, and the most consequential finding points the other way entirely.
These drugs are not metabolised by the liver enzymes that cause most interactions, so the usual list is almost empty. What replaces it is a single mechanical problem: everything you swallow now arrives late.
These drugs address the insulin resistance sitting underneath polycystic ovary syndrome, which is why they work. Restoring ovulation in women who believed they could not conceive is the part nobody prepares for.
Regulators on two continents investigated whether these drugs cause suicidal thoughts and concluded they do not. That finding settles a narrow question and leaves a much larger one open.
The cardiovascular benefit holds in older adults. So does the muscle loss, onto a body that was already losing muscle, in a person for whom a fall is a different event than it was at forty.
Almost every device problem people describe turns out to be one of six things, and the one that matters most is knowing when you have actually missed a dose.
Almost every side effect in this class follows the same shape: bad after a dose increase, better within a fortnight, mostly gone by the time you have been at a dose for two months. Almost.
Most of what determines how your first year goes is decided in the fortnight before the first injection, by questions nobody thinks to ask until much later.
Skin keeps tightening for a year or more after the weight stops coming off, which means most people who panic at month eight are looking at an unfinished result.
Berberine, apple cider vinegar, fibre blends and anything sold as a GLP-1 activator. Some of them do something measurable. None of them does the thing they are being bought for.
It is not a drug side effect. It is the face doing what the face has always done during rapid weight loss, in front of an audience that has never watched it happen this fast or this often.
Most side-effect lists are alphabetical, which tells you nothing about what will happen to you. This one is ordered by frequency, with the trial numbers attached and the rare ones kept in proportion.
Almost everyone on this drug class gets abdominal pain at some point. A very small number of them have something that needs an emergency department that evening, and the difference is learnable.
A stomach that empties slowly is a stomach that stays full longer, and a full stomach lying flat has only one direction to go. Most of the fix is mechanical rather than pharmacological.
Heat lowers blood pressure and removes fluid from a body that is already short of both. Nothing about it is dangerous in isolation, which is precisely why people underestimate the stack.
Most people sleep better on these drugs within a few months, for reasons that are entirely mechanical. A minority sleep considerably worse first, and almost nobody is warned about the interval.
The rotten-egg burp is one of the most reliably reported side effects on tirzepatide and one of the least discussed in clinic, largely because nobody wants to be the person raising it.
Every box in this class carries a boxed warning about thyroid tumours in rodents. Fifteen years of human data have not confirmed it, and the warning is still there — for reasons worth understanding.
Appetite suppression solves the quantity problem and creates a composition one. Every bite now has to do more work, and most people spend month one finding this out the hard way.
Abdomen, thigh or upper arm, and it genuinely does not matter which. What matters is the handful of things people do wrong in the ten seconds before the needle goes in.
The drug slows your stomach on purpose. Constipation is not a malfunction, it is the mechanism doing its job further down the tract than anyone wanted — which is why the fix is mechanical rather than clever.
Thirst tracks eating. Halve the food and you quietly halve the fluid and the sodium that came with it, which is why so much of what gets blamed on the drug is ordinary dehydration wearing a costume.
Every brand in this category claims transparency. Only some of them print the numbers that would let you check, and the gap between those two groups is the most useful thing a buyer can know.
Most of the supplements sold to people on Ozempic are designed to raise GLP-1. You are already injecting a GLP-1 agonist. The useful question is what the drug leaves behind, and which stack is built to replace it.
Most supplement advice for this drug is written for a generic body. Menstrual iron losses, bone density during rapid loss, and a documented contraceptive interaction make the picture genuinely different.
Berberine got called nature's Ozempic by people who had not looked closely at either. It is a real compound with real effects and a real interaction profile, and it is the one shelf in this market where I would want your prescriber involved before your wallet.
Slowed gastric emptying is the mechanism that makes these drugs work and the mechanism that stops your bowels. Whether a probiotic helps depends entirely on which of those two problems you actually have.
The hollowing people notice at month six is lost facial fat, not tired skin. Nothing in a bottle puts that back — which makes the honest question what a serum or a supplement can still usefully do.
Week one is not the time to build a stack. It is the time to find out how your body handles the drug, with the smallest number of variables you can manage.
Tiredness on these drugs has four common causes and only one of them is fixed by a supplement you can buy today. Working out which one you have is worth more than anything in this ranking.
Nausea is the mechanism, not a malfunction, which sets a hard ceiling on what any supplement can do. Within that ceiling there is one cheap option with real trial evidence and a great deal of expensive noise.
Semaglutide's signature is gastrointestinal. Nausea, reflux and constipation shape what you can physically swallow, which makes tolerability the first ranking criterion rather than an afterthought.
An entire industry has assembled around the answer being yes. The defensible answer is that two products help most people, two help some, and the rest exist because you are a motivated buyer with a new prescription.
Almost every avoidable failure I see in the first year of treatment traces back to the same thing: nobody wrote anything down. Here is what is worth recording, why it matters more on these drugs than on anything else I prescribe, and the tool I have settled on.
Fatty liver disease is common, largely undiagnosed, and now has a GLP-1 approved to treat it. For patients whose plans exclude weight-loss drugs, that is not a footnote — it is a different prescription.
Appetite usually changes in the first week. The scale takes considerably longer, and almost everything people believe about the timeline comes from watching someone else's month one.
The four-day rule, the reason it exists, and why the fix that feels most sensible — doubling up — is the one that puts people in the emergency department.
Nobody is short of opinions about these drugs. What people are short of is a clear account of the first two months — what the body does, when, and which parts of it are worth a phone call.
A trial stopped early for efficacy, a label expanded, and a benefit that has almost nothing to do with weight. If you have type 2 diabetes and chronic kidney disease, this is the most important thing in your file.
The mechanism is usually explained either in cartoon form or in a wall of pharmacology. Here is the version in between — enough to reason with, without pretending the picture is complete.
Hair shedding after starting a GLP-1 is real, common enough to be worth naming, and in most cases caused by the speed of the weight loss rather than the drug producing it.
Tirzepatide can reduce the effectiveness of oral contraceptives — after the first dose and after every increase. It is printed on the label, it is rarely mentioned in the appointment, and it has a specific four-week window attached to it.
Nobody measured it, no trial listed it as an endpoint, and it is the single most common thing patients volunteer unprompted. The most consequential effect of these drugs may be one we have no instrument for.
A 2024 study reported a higher rate of a rare optic nerve condition in semaglutide patients. Here is how to read a finding like that without either dismissing it or panicking.
The number is not the hard part. Getting a hundred and twenty grams into a body that stops being interested after four bites is a logistics problem, and it deserves to be treated as one.
There is a real difference between a licensed 503A pharmacy with a prescriber behind it and a website selling vials labelled 'not for human consumption'. Most people cannot tell them apart, and the marketing is designed that way.
A striking number of people on these drugs report simply losing interest in alcohol. It was nobody's design goal, the mechanism is unresolved, and it may turn out to be one of the most consequential things this class does.
Almost everyone is warned about nausea. Almost nobody is told what it should feel like, how long it should last, or which version of it means you should stop reading and call someone.
Also in Your Body
On The Jab
The
GLP‑1
Handbook
Dr. Nick Robertson
MD
The book · 14 chapters
Everything I tell my own patients before their first injection. 214 pages of what actually matters in the first year — dosing, side effects, food, muscle, cost, and the part nobody prepares you for: maintenance.
Priced at four dollars because it should be affordable to everyone taking these drugs — not because it's worth four dollars. No upsell, no course, no supplement line.